ZUMA-7 Subsequent Therapies and Real-World Outcomes of Axi-cel for LBCL by Race and Ethnicity

Dr Jeremy Abramson examines outcomes for patients in ZUMA-7 receiving subsequent treatment and real-world outcomes of axi-cel for LBCL by race and ethnicity, highlighting the need for better equity in access to CAR-T therapy.

Related Items

Conference Correspondent Coverage is Brought to You by the Publishers of:
American Health & Drug Benefits
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
Personalized Medicine in Oncology
The Oncology Nurse–APN/PA
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications